Literature DB >> 19898237

Antihuman leukocyte antigen antibody-induced autoimmunity: role in chronic rejection.

Dilip S Nath1, Haseeb Illias Basha, Thalachallour Mohanakumar.   

Abstract

PURPOSE OF REVIEW: We provide evidence for the role of de-novo development of immune responses to self-antigens in the posttransplant period and its possible induction by alloimmunity in the pathogenesis of chronic rejection following lung, heart and kidney transplantation. The present review details recent findings for the two distinct yet interdependent immune processes in the immunopathogenesis of chronic rejection. RECENT
FINDINGS: The contribution of both humoral and cell-mediated alloimmune responses against mismatched donor histocompatibility antigens (HLA) in the pathogenesis of chronic rejection is well established. Recent studies have focused on development of immune responses to self-antigens during the posttransplant period and its correlation with chronic rejection. These self-antigens include myosin and vimentin in cardiac, K-alpha-1-tubulin and collagen-V in lung and angiotensin II type 1 receptor, collagen-IV and VI in kidney transplants. During the posttransplant period, the development of immune responses to self-antigens is facilitated by induction of a distinct subset of autoreactive T-helper cells referred to as Th17 cells.
SUMMARY: Following organ transplantation, tissue injury and remodeling inflicted by antibodies (Abs) to HLA antigens is conducive to develop autoimmunity. Abs to HLA and self-antigens are detectable in the serum of transplant recipients who develop chronic rejection. Anti-HLA Abs are often present transiently but precede the development of Abs to self-antigens.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19898237      PMCID: PMC2806932          DOI: 10.1097/MOT.0b013e3283342780

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  40 in total

1.  Airway epithelial cell damage mediated by antigen-specific T cells: implications in lung allograft rejection.

Authors:  C R Smith; A Jaramillo; B F Duffy; T Mohanakumar
Journal:  Hum Immunol       Date:  2000-10       Impact factor: 2.850

Review 2.  Molecular mechanisms of chronic rejection following transplantation.

Authors:  Elbert Kuo; Takahiro Maruyama; Felix Fernandez; T Mohanakumar
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

3.  Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report--2006.

Authors:  David O Taylor; Leah B Edwards; Mark M Boucek; Elbert P Trulock; David A Waltz; Berkeley M Keck; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2006-07-10       Impact factor: 10.247

4.  CD4+25+ regulatory T cells limit Th1-autoimmunity by inducing IL-10 producing T cells following human lung transplantation.

Authors:  A Bharat; R C Fields; N Steward; E P Trulock; G A Patterson; T Mohanakumar
Journal:  Am J Transplant       Date:  2006-08       Impact factor: 8.086

5.  A new T-cell receptor transgenic model of the CD4+ direct pathway: level of priming determines acute versus chronic rejection.

Authors:  Todd V Brennan; Vunghi Hoang; Kym R Garrod; Feng-Chun Liu; Tracy Hayden; Jim Kim; Sang-Mo Kang
Journal:  Transplantation       Date:  2008-01-27       Impact factor: 4.939

6.  Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation.

Authors:  A Jaramillo; M A Smith; D Phelan; S Sundaresan; E P Trulock; J P Lynch; J D Cooper; G A Patterson; T Mohanakumar
Journal:  Transplantation       Date:  1999-04-27       Impact factor: 4.939

7.  Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection.

Authors:  Ankit Bharat; Kishore Narayanan; Tyler Street; Ryan C Fields; Nancy Steward; Aviva Aloush; Brian Meyers; Richard Schuessler; Elbert P Trulock; G Alexander Patterson; Thalachallour Mohanakumar
Journal:  Transplantation       Date:  2007-01-27       Impact factor: 4.939

8.  Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor.

Authors:  H S Leong; B M Mahesh; J R Day; J D Smith; A D McCormack; G Ghimire; T J Podor; M L Rose
Journal:  J Leukoc Biol       Date:  2007-11-01       Impact factor: 4.962

9.  IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants.

Authors:  William J Burlingham; Robert B Love; Ewa Jankowska-Gan; Lynn D Haynes; Qingyong Xu; Joseph L Bobadilla; Keith C Meyer; Mary S Hayney; Ruedi K Braun; Daniel S Greenspan; Bagavathi Gopalakrishnan; Junchao Cai; David D Brand; Shigetoshi Yoshida; Oscar W Cummings; David S Wilkes
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

10.  Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts.

Authors:  Peter T Jindra; Aileen Hsueh; Longshen Hong; David Gjertson; Xiu-Da Shen; Feng Gao; Julie Dang; Paul S Mischel; William M Baldwin; Michael C Fishbein; Jerzy W Kupiec-Weglinski; Elaine F Reed
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

View more
  27 in total

1.  Inhibition of renin angiotensin aldosterone system causes abrogation of obliterative airways disease through inhibition of tumor necrosis factor-α-dependant interleukin-17.

Authors:  Joseph Weber; Venkataswarup Tiriveedhi; Masashi Takenaka; Wei Lu; Ramsey Hachem; Elbert Trulock; G Alec Patterson; T Mohanakumar
Journal:  J Heart Lung Transplant       Date:  2012-01-29       Impact factor: 10.247

2.  Exosomes expressing the self-antigens myosin and vimentin play an important role in syngeneic cardiac transplant rejection induced by antibodies to cardiac myosin.

Authors:  Monal Sharma; Wei Liu; Sudhir Perincheri; Muthukumar Gunasekaran; T Mohanakumar
Journal:  Am J Transplant       Date:  2018-02-14       Impact factor: 8.086

3.  Cardiac allograft vasculopathy: a complex multifactorial sequela of heart transplantation.

Authors:  Ana Maria Segura; L Maximilian Buja
Journal:  Tex Heart Inst J       Date:  2013

Review 4.  The impact of infection and tissue damage in solid-organ transplantation.

Authors:  Anita S Chong; Maria-Luisa Alegre
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

5.  T regulatory cells play a significant role in modulating MHC class I antibody-induced obliterative airway disease.

Authors:  V Tiriveedhi; M Takenaka; S Ramachandran; A E Gelman; V Subramanian; G A Patterson; T Mohanakumar
Journal:  Am J Transplant       Date:  2012-07-23       Impact factor: 8.086

Review 6.  Alloimmunity and autoimmunity in chronic rejection.

Authors:  Anil Seetharam; Venkataswarup Tiriveedhi; T Mohanakumar
Journal:  Curr Opin Organ Transplant       Date:  2010-08       Impact factor: 2.640

7.  Ectopic B-cell clusters that infiltrate transplanted human kidneys are clonal.

Authors:  Julong Cheng; Ali Torkamani; Rajesh K Grover; Teresa M Jones; Diana I Ruiz; Nicholas J Schork; Michael M Quigley; F Wesley Hall; Daniel R Salomon; Richard A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-17       Impact factor: 11.205

8.  Lipid raft facilitated ligation of K-alpha1-tubulin by specific antibodies on epithelial cells: Role in pathogenesis of chronic rejection following human lung transplantation.

Authors:  Venkataswarup Tiriveedhi; Nataraju Angaswamy; Joseph Weber; T Mohanakumar
Journal:  Biochem Biophys Res Commun       Date:  2010-07-30       Impact factor: 3.575

9.  Role of alloimmunity and autoimmunity in allograft rejection.

Authors:  Babak Banan; Zhongping Xu; Muthukumar Gunasekaran; T Mohanakumar
Journal:  Clin Transpl       Date:  2013

Review 10.  The role of exosomes in allograft immunity.

Authors:  Sandhya Bansal; Monal Sharma; Ranjithkumar R; T Mohanakumar
Journal:  Cell Immunol       Date:  2018-06-07       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.